1,145 reports of this reaction
3.2% of all PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM reports
#4 most reported adverse reaction
OFF LABEL USE is the #4 most commonly reported adverse reaction for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, manufactured by Fresenius Kabi USA, LLC. There are 1,145 FDA adverse event reports linking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM to OFF LABEL USE. This represents approximately 3.2% of all 35,839 adverse event reports for this drug.
Patients taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,145 FDA reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 3.2% of all adverse event reports for PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, making it a notable side effect.
If you experience off label use while taking PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.